<DOC>
	<DOC>NCT00619697</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the efficacy on blood glucose control in type 2 diabetes.</brief_summary>
	<brief_title>Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes for at least 6 months Insulin naive. Short term insulin treatment (7 days or less within the last 6 months) is allowed Previous treatment with oral antidiabetic drugs for at least 4 months Judged by the investigator to be eligible for an insulin analogue plus oral antidiabetic drug treatment regimen BMI below 40 kg/m2 HbA1c between 712% Able and willing to perform selfplasma glucose monitoring The receipt of any other investigational drug within 4 weeks before screening A history of drug or alcohol abuse within the last 12 months Severe, uncontrolled hypertension Known or suspected allergy to trial products or related products</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>